![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Pharmacology and the Vascular Biology Center of Excellence, University of Tennessee Health Science Center, Memphis, Tennessee
Pulmonary fibroblasts regulate extracellular matrix production and degradation; thus, they are critical for maintenance of lung structure, function, and repair. In pulmonary fibrosis, fibroblasts produce excess collagen and form fibrotic foci that eventually impair lung function, but the mechanisms responsible for these alterations are not known. Receptors coupled to the stimulation of cAMP production can inhibit activation of fibroblasts and thereby are antifibrotic. To test whether this signaling pathway is altered in pulmonary fibrosis, we compared the ability of normal adult human pulmonary fibroblasts to generate and respond to cAMP with that of cells isolated from lungs with idiopathic pulmonary fibrosis. Serum- and transforming growth factor (TGF)-
-stimulated cell proliferation was inhibited
50% by forskolin and
100% by prostaglandin (PG) E2 in the normal cells but substantially less in the diseased cells. Collagen synthesis was also inhibited >50% by the same drugs in the normal cells but significantly less so in the diseased cells, despite responding with similar increases in cAMP production. Although expression of protein kinase A (PKA) and cAMP-stimulated PKA activity were similar in both the normal and diseased cell types, forskolin- and PGE2-stimulated cAMP response element-binding protein (CREB) phosphorylation was decreased in the diseased cell lines compared with the normal cells. cAMP-mediated activation and TGF-
-mediated inhibition of CREB DNA binding was also diminished in the diseased cells. Thus, pulmonary fibroblasts derived from patients with pulmonary fibrosis are refractory to the inhibition by cAMP due to altered activity of components distal to the activity of PKA, in particular the phosphorylation of CREB.
Address correspondence to: Dr. Rennolds S. Ostrom, Department of Pharmacology, University of Tennessee Health Science Center, 874 Union Ave., Crowe 115, Memphis, TN 38163. E-mail: rostrom{at}utmem.edu
This article has been cited by other articles:
![]() |
S. Togo, X. Liu, X. Wang, H. Sugiura, K. Kamio, S. Kawasaki, T. Kobayashi, R. F. Ertl, Y. Ahn, O. Holz, et al. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts Am J Physiol Lung Cell Mol Physiol, June 1, 2009; 296(6): L959 - L969. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jain, G. Chakraborty, R. Raja, S. Kale, and G. C. Kundu Prostaglandin E2 Regulates Tumor Angiogenesis in Prostate Cancer Cancer Res., October 1, 2008; 68(19): 7750 - 7759. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Huang, S. H. Wettlaufer, C. M. Hogaboam, K. R. Flaherty, F. J. Martinez, J. L. Myers, T. V. Colby, W. D. Travis, G. B. Toews, and M. Peters-Golden Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 66 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Huang, S. H. Wettlaufer, C. Hogaboam, D. M. Aronoff, and M. Peters-Golden Prostaglandin E2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling Am J Physiol Lung Cell Mol Physiol, February 1, 2007; 292(2): L405 - L413. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, S. Q. Sun, A. Hassid, and R. S. Ostrom cAMP Inhibits Transforming Growth Factor-beta-Stimulated Collagen Synthesis via Inhibition of Extracellular Signal-Regulated Kinase 1/2 and Smad Signaling in Cardiac Fibroblasts Mol. Pharmacol., December 1, 2006; 70(6): 1992 - 2003. [Abstract] [Full Text] [PDF] |
||||